TY - JOUR
T1 - Gene-specific somatic epigenetic mosaicism of FDFT1 underlies a non-hereditary localized form of porokeratosis
AU - Saito, Sonoko
AU - Saito, Yuki
AU - Sato, Showbu
AU - Aoki, Satomi
AU - Fujita, Harumi
AU - Ito, Yoshihiro
AU - Ono, Noriko
AU - Funakoshi, Takeru
AU - Kawai, Tomoko
AU - Suzuki, Hisato
AU - Sasaki, Takashi
AU - Tanaka, Tomoyo
AU - Inoie, Masukazu
AU - Hata, Kenichiro
AU - Kataoka, Keisuke
AU - Kosaki, Kenjiro
AU - Amagai, Masayuki
AU - Nakabayashi, Kazuhiko
AU - Kubo, Akiharu
N1 - Publisher Copyright:
© 2024 American Society of Human Genetics
PY - 2024/5/2
Y1 - 2024/5/2
N2 - Porokeratosis is a clonal keratinization disorder characterized by solitary, linearly arranged, or generally distributed multiple skin lesions. Previous studies showed that genetic alterations in MVK, PMVK, MVD, or FDPS—genes in the mevalonate pathway—cause hereditary porokeratosis, with skin lesions harboring germline and lesion-specific somatic variants on opposite alleles. Here, we identified non-hereditary porokeratosis associated with epigenetic silencing of FDFT1, another gene in the mevalonate pathway. Skin lesions of the generalized form had germline and lesion-specific somatic variants on opposite alleles in FDFT1, representing FDFT1-associated hereditary porokeratosis identified in this study. Conversely, lesions of the solitary or linearly arranged localized form had somatic bi-allelic promoter hypermethylation or mono-allelic promoter hypermethylation with somatic genetic alterations on opposite alleles in FDFT1, indicating non-hereditary porokeratosis. FDFT1 localization was uniformly diminished within the lesions, and lesion-derived keratinocytes showed cholesterol dependence for cell growth and altered expression of genes related to cell-cycle and epidermal development, confirming that lesions form by clonal expansion of FDFT1-deficient keratinocytes. In some individuals with the localized form, gene-specific promoter hypermethylation of FDFT1 was detected in morphologically normal epidermis adjacent to methylation-related lesions but not distal to these lesions, suggesting that asymptomatic somatic epigenetic mosaicism of FDFT1 predisposes certain skin areas to the disease. Finally, consistent with its genetic etiology, topical statin treatment ameliorated lesions in FDFT1-deficient porokeratosis. In conclusion, we identified bi-allelic genetic and/or epigenetic alterations of FDFT1 as a cause of porokeratosis and shed light on the pathogenesis of skin mosaicism involving clonal expansion of epigenetically altered cells.
AB - Porokeratosis is a clonal keratinization disorder characterized by solitary, linearly arranged, or generally distributed multiple skin lesions. Previous studies showed that genetic alterations in MVK, PMVK, MVD, or FDPS—genes in the mevalonate pathway—cause hereditary porokeratosis, with skin lesions harboring germline and lesion-specific somatic variants on opposite alleles. Here, we identified non-hereditary porokeratosis associated with epigenetic silencing of FDFT1, another gene in the mevalonate pathway. Skin lesions of the generalized form had germline and lesion-specific somatic variants on opposite alleles in FDFT1, representing FDFT1-associated hereditary porokeratosis identified in this study. Conversely, lesions of the solitary or linearly arranged localized form had somatic bi-allelic promoter hypermethylation or mono-allelic promoter hypermethylation with somatic genetic alterations on opposite alleles in FDFT1, indicating non-hereditary porokeratosis. FDFT1 localization was uniformly diminished within the lesions, and lesion-derived keratinocytes showed cholesterol dependence for cell growth and altered expression of genes related to cell-cycle and epidermal development, confirming that lesions form by clonal expansion of FDFT1-deficient keratinocytes. In some individuals with the localized form, gene-specific promoter hypermethylation of FDFT1 was detected in morphologically normal epidermis adjacent to methylation-related lesions but not distal to these lesions, suggesting that asymptomatic somatic epigenetic mosaicism of FDFT1 predisposes certain skin areas to the disease. Finally, consistent with its genetic etiology, topical statin treatment ameliorated lesions in FDFT1-deficient porokeratosis. In conclusion, we identified bi-allelic genetic and/or epigenetic alterations of FDFT1 as a cause of porokeratosis and shed light on the pathogenesis of skin mosaicism involving clonal expansion of epigenetically altered cells.
KW - FDFT1
KW - cholesterol
KW - clonal expansion
KW - epigenetic mosaicism
KW - germline variant
KW - mevalonate pathway
KW - porokeratosis
KW - promoter hypermethylation
KW - somatic variant
KW - statin
UR - http://www.scopus.com/inward/record.url?scp=85191306032&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85191306032&partnerID=8YFLogxK
U2 - 10.1016/j.ajhg.2024.03.017
DO - 10.1016/j.ajhg.2024.03.017
M3 - Article
C2 - 38653249
AN - SCOPUS:85191306032
SN - 0002-9297
VL - 111
SP - 896
EP - 912
JO - American Journal of Human Genetics
JF - American Journal of Human Genetics
IS - 5
ER -